Stempeutics has moved from Phase I/II to Phase II clinical trials in Bangalore, with their Allogenic Mesenchymal Stem cells. Results of Phase II should be published in 2014.
This treatment has already proven effective in repairing lungs for transplant, and Stempeutics will be the first company worldwide, to have an off the shelf product for certain types of lung damage.
This treatment has already proven effective in repairing lungs for transplant, and Stempeutics will be the first company worldwide, to have an off the shelf product for certain types of lung damage.